Overview of the 3rd isirv-Antiviral Group Conference - advances in clinical management

Influenza and other Respiratory Viruses

Volumn 9, Issue 1, 2015, Pages 20-31

  Hurt, Aeron C ^a,b   Hui, David S ^c   Hay, Alan ^d   Hayden, Frederick G ^e  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antivirals; Clinical management; Immunocompromised; Influenza; Respiratory; Treatment

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

COMMUNICABLE DISEASE; CORONAVIRUS INFECTIONS; HUMAN; IMMUNOCOMPROMIZED PATIENT; INFLUENZA, HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIROLOGY; VIRUS DISEASES;

ANTIVIRAL AGENTS; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PANDEMICS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIRUS DISEASES;

EID: 84919471395     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12293     Document Type: Article

References (113)

1. Programme of the third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan. Available at: http://www.isirv.org/site/images/stories/avg/documents/intranet/Tokyo/programe_abstract_book.pdf (Accessed 1 September 2014). Website 2014.
2. CDC. Influenza Risk Assessment Tool (IRAT). Available at: http://www.cdc.gov/flu/pandemic-resources/tools/risk-assessment.htm (Accessed 1 September 2014). Website 2014.
3. WHO. Overview of the emergence and characteristics of the avian influenza A(H7N9) virus. Available at: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/WHO_H7N9_review_31May13.pdf (Accessed 1 September 2014). Website 2013.
4. WHO. Confirmed human cases of avian influenza A(H7N9) reported to WHO. Available at: http://www.who.int/influenza/human_animal_interface/influenza_h7n9/17_ReportWebH7N9Number_20140408.pdf?ua=1 (Accessed 1 September 2014). Website 2014.
5. Gao HN, Lu HZ, Cao B et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013; 368:2277-2285.
6. Yu H, Wu JT, Cowling BJ et al. Effect of closure of live poultry markets on poultry-to-person transmission of avian influenza A H7N9 virus: an ecological study. Lancet 2014; 383:541-548.
7. Bai T, Zhou J, Shu Y. Serologic study for influenza A (H7N9) among high-risk groups in China. N Engl J Med 2013; 368:2339-2340.
8. Shu Y. H7N9 in China: Virologic and Epidemiologic Features. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation PS1-2.
9. Zhou J, Wang D, Gao R et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013; 499:500-503.
10. Dortmans JC, Dekkers J, Wickramasinghe IN et al. Adaptation of novel H7N9 influenza A virus to human receptors. Sci Rep 2013; 3:3058.
11. Ho PL, Sin WC, Chan JF et al. Severe influenza A H7N9 pneumonia with rapid virological response to intravenous zanamivir. Eur Respir J 2014; 44:535-537.
12. Hu Y, Lu S, Song Z et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381:2273-2279.
13. Hai R, Schmolke M, Leyva-Grado VH et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013; 4:2854.
14. Yen HL, Zhou J, Choy KT et al. The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets. J Infect Dis 2014; pii: jiu353 [Epub ahead of print].
15. Rith S, Horm SV, Sok T et al. Molecular Epidemiology of Influenza A/H5N1 Clade 1 circulation in Cambodia. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation O2.
16. WHO. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2014. Available at http://www.who.int/influenza/human_animal_interface/EN_GIP_20140124CumulativeNumberH5N1cases.pdf. Website 2014.
17. Dejpichai R, Laosiritaworn Y, Phuthavathana P et al. Seroprevalence of antibodies to avian influenza virus A (H5N1) among residents of villages with human cases, Thailand, 2005. Emerg Infect Dis 2009; 15:756-760.
18. Aditama TY, Samaan G, Kusriastuti R et al. Avian influenza H5N1 transmission in households, Indonesia. PLoS One 2012; 7:e29971.
19. Adisasmito W, Chan PK, Lee N et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202:1154-1160.
20. Chan PK, Lee N, Zaman M et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis 2012; 206:1359-1366.
21. Patel RB, Mathur MB, Gould M et al. Demographic and clinical predictors of mortality from highly pathogenic avian influenza A (H5N1) virus infection: CART analysis of international cases. PLoS One 2014; 9:e91630.
22. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358:261-273.
23. WHO Representative Office China. WHO China statement on H5N6. Available at http://www.wpro.who.int/china/mediacentre/releases/2014/20140507/en/. Website 2014.
24. Chen H, Yuan H, Gao R et al. Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. Lancet 2014; 383:714-721.
25. Nakai A, Minakami H, Unno N et al. Characteristics of pregnant Japanese women who required hospitalization for treatment of pandemic (H1N1) 2009-low mortality rate may be due to early antiviral use. J Infect 2011; 62:232-233.
26. Nakai A, Saito S, Unno N et al. Review of the pandemic (H1N1) 2009 among pregnant Japanese women. J Obstet Gynaecol Res 2012; 38:757-762.
27. Chaw L, Burmaa A, Kamigaki T et al. Epidemiology of influenza infection among pregnant women and childrn under 6 months in Mongolia, 2013/14 Season: A prospective Cohort Study. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation O4.
28. Dar L, Kumar R, Singh Y et al. Influenza viruses in children from a rural indian community: a post-pandemic surveillance study. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation P56.
29. WHO. Vaccines against influenza WHO position paper - November 2012. Wkly Epidemiol Rec 2012; 87:461-476.
30. Virk RK, Gunalan V, Tan BH et al. Molecular evidence of transmission of influenza on a university campus in Singapore. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation P31.
31. Cowling BJ, Ip DK, Fang VJ et al. Aerosol transmission is an important mode of influenza A virus spread. Nat Commun 2013; 4:1935.
32. Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J Infect Chemother 2011; 17:595-601.
33. Sugaya N, Tamura D, Yamazaki M et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008; 47:339-345.
34. Sugaya N, Mitamura K, Yamazaki M et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202.
35. Koseki N, Kaiho M, Kikuta H et al. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season. Influenza Other Respir Viruses 2014; 8:151-158.
36. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395-404.
37. Kashiwagi S, Watanabe A, Ikematsu H et al. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother 2013; 19:740-749.
38. Oh DY, Lowther S, McCaw JM et al. Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact. J Antimicrob Chemother 2014; 69:2458-2469;%19. pii: dku146.
39. Saito R, Sato I, Suzuki Y et al. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation. Pediatr Infect Dis J 2010; 29:898-904.
40. Takashita E, Ejima M, Itoh R et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill 2014; 19:20666.
41. Hurt AC, Hardie K, Wilson NJ et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365:2541-2542.
42. Hurt AC, Hardie K, Wilson NJ et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148-157.
43. Butler J, Hooper KA, Petrie S et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog 2014; 10:e1004065.
44. Yates PJ, Mehta N, Hasan S et al. Identification of resistance mutations as minority species in clinical specimens from hospitalised adults with influenza and treated with intravenous zanamivir. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation P19.
45. Burnham AJ, Baranovich T, Marathe BM et al. Fitness costs for influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the Importance of E119A and H274Y. Antimicrob Agents Chemother 2014; 58:2718-2730.
46. Furukawa H, Murayama M, Soutome T et al. Safety and efficacy of intravenous zanamivir in the treatment of hospitalised Japanese patients with influenza infection. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation P34.
47. Kirillova ES, Garaev TM, Shibnev VA et al. New adamantane derivatives can overcome resistance of influenza A(H1N1)pdm09 and A(H3N2) viruses to rimantadine. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation P18.
48. Smee DF, Tarbet EB, Furuta Y et al. Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol 2013; 8:1085-1094.
49. Trevejo J, Deng R, Burgess T et al. Safety and efficacy of MHAA4549A, a novel monoclonal antibody for treatment of severe influenza A. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation O8.
50. Lin SC, Liu WC, Jan JT et al. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One 2014; 9:e92822.
51. Nicol MQ, Ligertwood Y, Bacon MN et al. A novel family of peptides with potent activity against influenza A viruses. J Gen Virol 2012; 93:980-986.
52. Marjuki H, Mishin VP, Chesnokov AP et al. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality. J Infect Dis 2014; 210:435-440.
53. Moss RB, Hansen C, Sanders RL et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012; 206:1844-1851.
54. Connaris H, Govorkova EA, Ligertwood Y et al. Prevention of influenza by targeting host receptors using engineered proteins. Proc Natl Acad Sci USA 2014; 111:6401-6406.
55. Govorkova EA, Connaris H, Taylor MA et al. Prevention of lethal H7N9 influenza virus infection by a novel receptor-binding protein. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation O14.
56. Singanayagam A, Cocking R, Moncorge O et al. 2009 pandemic H1N1 influenza can rapidly develop escape mutations in the presence of a host-directed vacuolar ATPase inhibiting drug. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation P39.
57. Kissling E, Valenciano M, Buchholz U et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Euro Surveill 2014; 19:20701.
58. Shinjoh M, Sekiguchi S, Iwata S et al. Estimated effectiveness of influenza vaccine using influenza rapid diagnostic tests - test-negative case-control study among Japanese Children. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation P10.
59. van Essen GA, Beran J, Devaster JM et al. Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza Other Respir Viruses 2014; 8:452-462.
60. Fluzone high-dose vaccine is significantly more effective than the standard dose of fluzone vaccine in preventing influenza in adults ≥65 years of age. Clin Infect Dis 2013; 57:i.
61. Kawaoka Y. Current progress in influenza research. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation ES.
62. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) - update, Disease outbreak news, 14 July 2014. Available at http://www.who.int/csr/don/2014_07_14_mers/en/. Website 2014.
63. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update-as of 11 June 2014. Available at http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf?ua=1. Website 2014.
64. Public Health England/ISARIC. Treatment of MERS-CoV: Information for Clinicians, Clinical decision-making support for treatment of MERS-CoV patients. Available at http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416. Website 2014.
65. Alagaili AN, Briese T, Mishra N et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 2014; 5:e00884-14.
66. Cauchemez S, Fraser C, Van Kerkhove MD et al. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 2014; 14:50-56.
67. Zambon M. MERS-CoV situation update. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation PS1-4.
68. Galiano M, Myers R, Faria NR et al. Inferring intra-and inter-host MERS-CoV evolutionary dynamics in a transmission chain by deep whole genome sequencing. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation O1.
69. Auyeung TW, Lee JS, Lai WK et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 2005; 51:98-102.
70. Chan JF, Chan KH, Kao RY et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606-616.
71. Mair-Jenkins J, Saavedra-Campos M, Baillie K et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. J Infect Dis 2014; jiu396 [Epub ahead of print].
72. PHE/ISARIC. Treatment of MERS-CoV:Decision Support Tool, Clinical Decision Making Tool for Treatment of MERS-CoV v.1.1, 29 July, 2013; https://isaric.tghn.org/site_media/media/articles/Decision_Support_Document_v1_1_20130729.pdf. Website 2014.
73. Nair H, Nokes DJ, Gessner BD et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375:1545-1555.
74. DeVincenzo JP. Factors predicting childhood respiratory syncytial virus severity: what they indicate about pathogenesis. Pediatr Infect Dis J 2005; 24:S177-S183; discussion.
75. Lee N, Lui GC, Wong KT et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013; 57:1069-1077.
76. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537.
77. Blanken MO, Rovers MM, Molenaar JM et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368:1791-1799.
78. Ramilo O, Lagos R, Saez-Llorens X et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J 2014; 33:703-709.
79. Kimura H, Tsukagoshi H, Ryo A et al. Molecular Epidemiology of Human Rhinovirus (HRV) in Patients with Asthma. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation PS6-2.
80. Djukanovic R, Harrison T, Johnston SL et al. The effect of inhaled ifn-beta on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med 2014; 190:145-154.
81. Matz J. Vapendavir for The Treatment Of Naturally Acquired Rhinovirus Infection In Asthmatic Adults: Effect On Asthma Control In A Phase 2 Clinical Trial. American Thoracic Society Conference 2013 2013; Poster Board # C17; Publication Page: A5497.
82. Jennings L. Advances in diagnostics for influenza and RVI's. Influenza and Other Respiratory Virus Infections: Advances in Clinical Management, Third isirv-Antiviral Group Conference, June 4-6, 2014, Tokyo, Japan 2014; Presentation PS3-1.
83. Ruggiero P, McMillen T, Tang YW et al. Evaluation of the BioFire FilmArray respiratory panel and the GenMark eSensor respiratory viral panel on lower respiratory tract specimens. J Clin Microbiol 2014; 52:288-290.
84. Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 2014; 100:94-103.
85. Haffizulla J, Hartman A, Hoppers M et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis 2014; 14:609-618.
86. Rossignol JF. Nitazoxanide: A new broad spectrum antiviral agent against respiratory virus efficacy, resistance and mechnaism of action. 9th Australian Influenza Symposium, 3-4 October 2013, Sydney, Australia 2014; D2.P4.
87. Hui DS, Lee N. Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respir Viruses 2013; 7(Suppl 3):52-59.
88. Lee N, Allen CK, Hui DS et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31:304-309.
89. Annane D, Bellissant E, Bollaert PE et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301:2362-2375.
90. Leuppi JD, Schuetz P, Bingisser R et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309:2223-2231.
91. Fernandes RM, Bialy LM, Vandermeer B et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2013; 6:CD004878.
92. Bridevaux PO, Aubert JD, Soccal PM et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax 2014; 69:32-38.
93. Memoli MJ, Athota R, Reed S et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014; 58:214-224.
94. Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis 2011; 24:333-343.
95. Choi SM, Xie H, Campbell AP et al. Influenza viral RNA detection in blood as a marker to predict disease severity in hematopoietic cell transplant recipients. J Infect Dis 2012; 206:1872-1877.
96. Boudreault AA, Xie H, Leisenring W et al. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant 2011; 17:979-986.
97. Carr S, Ilyushina NA, Franks J et al. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr Infect Dis J 2011; 30:284-288.
98. Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521-526.
99. Choi SM, Boudreault AA, Xie H et al. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 2011; 117:5050-5056.
100. Protheroe RE, Kirkland KE, Pearce RM et al. The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study. Bone Marrow Transplant 2012; 47:88-94.
101. Reid G, Huprikar S, Patel G et al. A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients. Transpl Infect Dis 2013; 15:487-492.
102. Seo S, Englund JA, Nguyen JT et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther 2013; 18:377-386.
103. Renaud C, Pergam SA, Polyak C et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010; 12:513-517.
104. Dulek DE, Williams JV, Creech CB et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50:1493-1496.
105. Ison MG, Sharma A, Shepard JA et al. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008; 27:282-288.
106. Hayden FG. Newer influenza antivirals, biotherapeutics and combinations. Influenza Other Respir Viruses 2013; 7(Suppl 1):63-75.
107. Chalkias S, Mackenzie MR, Gay C et al. DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation. Transpl Infect Dis 2014; 16:141-144.
108. Waghmare A, Wagner T, Andrews R et al. Successful treatment of parainfluenza virus (PIV) respiratory infection with DAS181 in 3 immunocompromised children. ID Week 2013, October 2-6, 2013, San Francisco, USA 2013; Presentation 472.
109. Zamora MR, Budev M, Rolfe M et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183:531-538.
110. Simon A, Karstemn V, Cehelsky J et al. Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients. European Respiratory Society, Vienna, 2012 2012; Presentation P1476.
111. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 2004; 23:583-588.
112. Marty FM, Winston DJ, Rowley SD et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369:1227-1236.
113. Florescu DF, Pergam SA, Neely MN et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012; 18:731-738.